Results of a recent Polish study show that the drug Mozobil may help multiple myeloma patients who previously had a stem cell transplant collect enough stem cells for a second transplant.

However, the results also showed that previously transplanted patients collected fewer stem cells than patients who had not received a stem cell transplant before.

According to the study authors, these results showed for the first time that Mozobil (plerixafor) is highly effective for previously transplanted myeloma patients.

Autologous stem cell transplantation, a common treatment option for younger, newly…

The number of stem cells harvested from multiple myeloma patients during the first day of collection predicts the success of the entire collection procedure, according to a recent study.  Those patients with higher stem cell counts on the first day of collection are more likely to collect enough stem cells for transplantation.

The authors of the study suggested that patients with very low counts of blood forming stem cells on day one of collection should be treated with Mozobil (plerixafor), a drug used to mobilize stem cells from the…

A recent Phase 2 study, published in the journal Bone Marrow Transplantation, evaluated Mozobil’s (plerixafor) ability to mobilize stem cells from the bone marrow into the blood without increasing the mobility of tumor cells in multiple myeloma patients.

One common treatment option available to eligible myeloma patients is high dose chemotherapy followed by autologous stem cell transplantation. Before chemotherapy, the patient’s own stem cells are collected by peripheral blood apheresis, which looks and feels similar to a routine blood donation, and then the stem cells are transplanted back after…

The Committee for Human Medicinal Products of the European Medicines Agency has recommended that the stem cell transplant drug Mozobil (plerixafor) be approved for use in the European Union.

Mozobil is used for stem cells transplants in patients with blood cancers, specifically non-Hodgkin’s lymphoma and multiple myeloma. Combined with other drugs that stimulate the body’s production of stem cells, Mozobil helps move stem cells from the bone marrow into the bloodstream, where they can be collected for subsequent transplants.

Traditionally, the collection of stem cells for transplantation has been a process…

A new study in the journal Blood shows that adding Mozobil (plerixafor) to Neupogen (filgrastim) prior to stem cell harvesting significantly increases harvest efficiency.

Mozobil is a new drug designed to mobilize stem cells from the bone marrow into the bloodstream, where they can be collected. Neupogen, which is commonly given prior to stem cell harvesting, stimulates the body to make white blood cells.

When given together, Mozobil and Neupogen have been shown to increase harvest efficiency in myeloma patients prior to autologous peripheral stem cell transplantation. The U.S. Food and…